ATLANTA -- Islet cell xenotransplantation presents a promising near-term solution to the critically low islet cell supply for humans suffering from type 1 diabetes, according to researchers from the Emory Transplant Center, the Yerkes National Primate Research Center of Emory University and the University of Alberta, Canada. The Emory/Yerkes researchers successfully transplanted and engrafted insulin-producing neonatal porcine islet cells harvested by the University of Alberta researchers into diabetic rhesus macaque monkeys, restoring the monkeys' glucose control and resulting in sustained insulin independence. This research, published in the February 26 advanced online edition of Nature Medicine, also examines the effectiveness of a costimulation blockade-based regimen developed at Emory proven to have fewer toxic side effects than currently used immunosuppressive regimens, and provides essential answers to the possibility of cross-species viral transmission, a common concern of xenotransplantation use in humans.
If we had a much larger effort aimed at implementing all the Strategies for Engineered Negligible Senescence (SENS) there'd be a lot more money available for genetically engineering pigs to become more immuno-compatible with humans. That would make xenotransplantation a lot easier.
We need replacement parts. We should be trying much harder to develop them.
|Share |||Randall Parker, 2006 March 09 09:32 PM Biotech Organ Replacement|